Dr. De-Shen Wang, M.D., PhD, is currently a professor in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. He has extensive experience and expertise in the field of GI medical oncology and translation research in GI cancers. Dr. Wang has published over 80 peer-reviewed articles as first author or corresponding author in renowned journals such as JAMA Oncology, Gut, Drug Resistance Updates, PLOS Medicine, and Cancer Research. He is an editorial board member of the Journal of Drug Resistance Updates and a reviewer of more than 30 peer-reviewed journals. He was awarded many prizes including the First Prize of Chinese Medical Science and Technology Award, the First Prize of Guangdong Province Science and Technology Progress Award, and the Outstanding Youth Program of Guangdong Provincial Natural Science Foundation. He currently presides over several research programs including the Guangdong Provincial Natural Science program, and the general program from the National Natural Science Foundation of China.

He specializes in gastrointestinal cancer with a particular research focus on cancer treatment and drug resistance. 

Dr Wang received his Ph.D in clinical oncology from Sun Yat-Sen University and has completed training as a visiting scholar at St. John’s University, USA.

1. Ye LF, Huang ZY, Chen XX, Chen ZG, Wu SX, Ren C, Hu MT, Bao H, Jin Y, Wang F, Wang FH, Du ZM, Wu X, Ju HQ, Shao Y, Li YH^*, Xu RH^*, Wang DS^*. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. Drug Resist Updat. 2022 Sep 29;65:100883.

2. Wang DS^#, Liu ZX^#, Lu YX^#, Bao H, Wu X, Zengs ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW, Xu RH. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut, 2019 Jul;68(7):1152-1161.

3. Liu GY^#, Li WZ^#, Wang DS^#, Liang H, Lv X, Ye YF, Zhao C, Ke LR, Lv SH, Lu N, Bei WX, Cai ZC, Chen X, Liang CX, Guo X, Xia WX, Xiang YQ. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Apr 1;8(4):553-561.

4. Wang DS^#, Ren C^#, Li SS^#, Fong WP^#, Wu XJ^#, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF^*, Xu RH^*, Li YH^*. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS Med. 2024 May 10;21(5):e1004389.

5. Zheng YQ, Yang PC, Chen JY, Yu K, Ye YZ, Zhang L, Hou XH^*, Wang DS^*. Endoscopic excision as a viable alternative to major resection for early duodenal cancers: A population-based cohort study. Int J Surg. 2022 Apr 29:106644.

6. Wang DS^#, Hu MT^#, Wang ZQ^#, Ren C, Qiu MZ, Luo HY, Jin Y, Fong WP, Wang SB, Peng JW, Zou QF, Tan Q, Wang FH, Li YH. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open. 2021 Apr 1;4(4):e215250.

7. Liu J, Liu ZX, Li JJ, Zeng ZL, Wang JH, Luo XJ, Wong CW, Zheng JB, Pu HY, Mo HY, Sheng H, Wu QN, Li H, Wan G, Li B, Wang DS^*, Xu RH^*, Ju HQ^*. The macrophage-associated lncRNA MALR facilitates ILF3 liquid-liquid phase separation to promote HIF1α signaling in esophageal cancer. Cancer Res (2023) 83 (9): 1476–1489.

8. Wen L, Chen ZG, Ji XM, Fong WP, Shao Q, Ren C, Cai YY, Li BK, Yuan YF, Wang DS^*, Li YH^*. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. J Immunother Cancer. 2022 Jul;10(7):e004487.

9. Wang DS^#, Yang H^#, Liu XY, Chen ZG, Wang Y, Fong WP, Hu MT, Zheng YC, Zheng Y, Li BK, Yuan YF, Chen G, Pan ZZ, Song L, Li YH, Xu RH. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Theranostics 2021; 11(14):7018-7028.

10. Liang JY^#, Wang DS^# (co-first author), Lin HC, Chen XX, Yang H, Zheng Y, Li YH. A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci. 2020 Jul 6;16(13):2430-2441.

11. Wang W, Ye LF, Bao H, Hu MT, Han M, Tang HM, Ren C, Wu X, Shao Y, Wang FH, Zhou ZW, Li YH, Xu RH, Wang DS^*. Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma. Gastric Cancer. 2022 Nov;25(6):1017-1030.

12. Zheng JB, Wong CW, Liu J, Luo XJ, Zhou WY, Chen YX, Luo HY, Zeng ZL, Ren C, Xie XM^*, Wang DS^*. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. OncoImmunology. 2022 May 25;11(1):2079182.

Updated by International Office, Sun Yat-sen University Cancer Center